Eric P Krenning
Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate
Forrer F, de Herder W, van Lom K, de Jong M, Teunissen J, Bakker W, Konijnenberg M, Bernard B, Kooij P, Krenning E, Kwekkeboom D. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging 2009; 36:1138-46.
Feb 27, 2009Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate
Feb 27, 2009Eur J Nucl Med Mol Imaging 2009; 36:1138-46
Forrer Flavio, de Herder Wouter W, van Lom Kirsten, de Jong Marion, Teunissen Jaap J M, Bakker Willem H, Konijnenberg Mark, Bernard Bert F, Kooij Peter P, Krenning Eric P, Kwekkeboom Dik J
SPECT study of folate receptor-positive malignant and normal tissues in mice using a novel 99mTc-radiofolate
Müller C, Forrer F, Schibli R, Krenning E, de Jong M. SPECT study of folate receptor-positive malignant and normal tissues in mice using a novel 99mTc-radiofolate. J Nucl Med 2008; 49:310-7.
Jan 16, 2008SPECT study of folate receptor-positive malignant and normal tissues in mice using a novel 99mTc-radiofolate
Jan 16, 2008J Nucl Med 2008; 49:310-7
Müller Cristina, Forrer Flavio, Schibli Roger, Krenning Eric P, de Jong Marion
Dose-dependent effects of (anti)folate preinjection on 99mTc-radiofolate uptake in tumors and kidneys
Müller C, Schibli R, Forrer F, Krenning E, de Jong M. Dose-dependent effects of (anti)folate preinjection on 99mTc-radiofolate uptake in tumors and kidneys. Nucl Med Biol 2007; 34:603-8.
Aug 1, 2007Dose-dependent effects of (anti)folate preinjection on 99mTc-radiofolate uptake in tumors and kidneys
Aug 1, 2007Nucl Med Biol 2007; 34:603-8
Müller Cristina, Schibli Roger, Forrer Flavio, Krenning Eric P, de Jong Marion
Neuroendocrine tumors. Peptide receptor radionuclide therapy
Forrer F, Valkema R, Kwekkeboom D, de Jong M, Krenning E. Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 2007; 21:111-29.
Mar 1, 2007Neuroendocrine tumors. Peptide receptor radionuclide therapy
Mar 1, 2007Best Pract Res Clin Endocrinol Metab 2007; 21:111-29
Forrer Flavio, Valkema Roelf, Kwekkeboom Dik J, de Jong Marion, Krenning Eric P
Diagnostic versus therapeutic doses of [(177)Lu-DOTA-Tyr(3)]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organs
Müller C, Forrer F, Bernard B, Melis M, Konijnenberg M, Krenning E, de Jong M. Diagnostic versus therapeutic doses of [(177)Lu-DOTA-Tyr(3)]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organs. Cancer Biother Radiopharm 2007; 22:151-9.
Feb 1, 2007Diagnostic versus therapeutic doses of [(177)Lu-DOTA-Tyr(3)]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organs
Feb 1, 2007Cancer Biother Radiopharm 2007; 22:151-9
Müller Cristina, Forrer Flavio, Bernard Bert F, Melis Marleen, Konijnenberg Mark, Krenning Eric P, de Jong Marion
From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99m)Tc-DMSA-SPECT and molecular imaging
Forrer F, Rolleman E, Bijster M, Melis M, Bernard B, Krenning E, de Jong M. From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99m)Tc-DMSA-SPECT and molecular imaging. Cancer Biother Radiopharm 2007; 22:40-9.
Feb 1, 2007From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99m)Tc-DMSA-SPECT and molecular imaging
Feb 1, 2007Cancer Biother Radiopharm 2007; 22:40-9
Forrer Flavio, Rolleman Edgar, Bijster Magda, Melis Marleen, Bernard Bert, Krenning Eric P, de Jong Marion
Anaphylactoid reaction from amifostine
Rolleman E, Forrer F, Deckers J, de Groot H, Valkema R, de Jong M, Krenning E. Anaphylactoid reaction from amifostine. Radiother Oncol 2006; 82:110-1; author reply 111.
Dec 20, 2006Anaphylactoid reaction from amifostine
Dec 20, 2006Radiother Oncol 2006; 82:110-1; author reply 111
Rolleman Edgar J, Forrer Flavio, Deckers Jaap, de Groot Hans, Valkema Roelf, de Jong Marion, Krenning Eric P
Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate
Rolleman E, Forrer F, Bernard B, Bijster M, Vermeij M, Valkema R, Krenning E, de Jong M. Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2006; 34:763-771.
Dec 5, 2006Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate
Dec 5, 2006Eur J Nucl Med Mol Imaging 2006; 34:763-771
Rolleman Edgar J, Forrer Flavio, Bernard Bert, Bijster Magda, Vermeij Marcel, Valkema Roelf, Krenning Eric P, de Jong Marion